Core Viewpoint - China Pharmaceutical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. has received the Certificate of Suitability (CEP) for Clindamycin Phosphate from the European Directorate for the Quality of Medicines (EDQM), which enhances the company's ability to enter European and other markets that recognize the CEP certificate [1] Group 1 - The CEP certificate signifies that the Clindamycin Phosphate product meets the standards for chemical raw materials, allowing the company to expand its international business [1] - Clindamycin Phosphate is a lincosamide antibiotic primarily used for treating infections caused by Gram-positive bacteria and anaerobic bacteria [1] - The approval of the CEP certificate is expected to strengthen the company's product competitiveness in the global market [1]